Xylexx 20 mg/ml solution for injection for cattle, horses, dogs and cats

Authorised

- Xylazine

Product identification

Medicine name:
Xylexx 20 mg/ml solution for injection for cattle, horses, dogs and cats
Xylexx 20 mg/ml injekčný roztok pre hovädzí dobytok, kone, psy a mačky

Active substance:
Xylazine

Target species:
Cat
Cattle
Dog
Horse

Route of administration:
Subcutaneous use
Intramuscular use
Intravenous use

Product details

Active substance and strength:

Xylazine
20.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Cat**

Intramuscular use:

- **Cattle**
  - Meat and offal. 1 day 1 day
- **Dog**
- **Cat**

Intravenous use:

- **Horse**
  - Meat and offal. 1 day 1 day
- **Cattle**
  - Meat and offal. 1 day 1 day
  - Milk. no withdrawal period 0 hours

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QN05CM92

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Slovakia

Package description:
Clear type II glass vials containing 30 ml product, closed with a bromobutyl rubber stopper and aluminium cap in a polystyrene box.

Clear type II glass vials containing 30 ml product, closed with a bromobutyl rubber stopper and aluminium cap in a cardboard box
Clear type II glass vials containing 30 ml product, closed with a bromobutyl rubber stopper and aluminium cap in a cardboard or polystyrene box

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Alfasan Nederland B.V.

Marketing authorisation date:
16/12/2022

Manufacturing sites for batch release:
Alfasan Nederland B.V.

Responsible authority:
USKVBL

Authorisation number:
96/045/DC/22-S

Date of authorisation status change:
16/12/2022

Reference member state:
Netherlands

Procedure number:
NL/V/0366/001/DC

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland

France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 28/11/2022
Download
